ISRCTN66329631已完成未知
icotine plasma concentrations, pharmacokinetics and pharmacodynamics of single doses of flavored non-tobacco-based nicotine pouches (ZYN ULTRA) in current, daily snus users
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Willing and able to give written informed consent for participation in the study
- •2. Subjects who have used oral tobacco/nicotine products for =1 year, with a minimum daily consumption of five or more pouches, preferably brands with nicotine content =1%, and is willing and able to use brands with nicotine content =1%
- •3. Healthy male or female subject aged =19 years
- •4. Clinically normal medical history, physical findings, vital signs, ECG, and laboratory values at the time of screening, as judged by the investigator
- •5. WOCBP must be willing to use a sufficient contraceptive method for the duration of the study, this includes mechanical barrier (e.g., a male condom or a female diaphragm), combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal anticonception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device (IUD) or intrauterine system (IUS). Sexual abstinence is allowed when this is the preferred and usual lifestyle of the subject
排除标准
- •1. A history or presence of diagnosed hypertension or any cardiovascular disease.
- •2. Any surgical or medical condition, including abnormal salivation (also pharmaceutically induced), or history thereof, which, in the judgment of the investigator, might interfere with the absorption, distribution, metabolism or excretion of the investigational product or may either put the subject at risk because of participation in the study, influence the results, or the subject’s ability to participate in the study.
- •3. Subjects who are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
- •4. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency Virus (HIV).
- •5. A history of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity to similar flavoring agents as those found in the IPs (e.g. spearmint in toothpaste) as judged by the investigator.
- •Clinical Study Protocol SM20-02 Final v1.0; 07DEC2020
- •CONFIDENTIAL 28 (55)
- •6. Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to first administration of the IP. Positive results that are expected given the subject’s medical history and prescribed medications can be disregarded as judged by the investigator.
- •7. Current or history of alcohol abuse and/or use of anabolic steroids or drugs of abuse, as judged by the investigator.
- •8. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
- •9. Subjects who intend to change their nicotine consumption habit, including the intention to stop using nicotine products, within the next three months from the screening visit, as judged by the investigator.
- •10. The investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
研究者
相似试验
已完成
Unknown
Plasma nicotine concentrations following single doses of new-format nicotine pouchesicotine useISRCTN13589495Swedish Match North Europe AB38
已完成
不适用
Effects of flavors in oral tobacco-derived nicotine pouches on nicotine exposureicotine useISRCTN91637022Swedish Match North Europe AB42
已完成
不适用
A study investigating the uptake to the blood circulation of nicotine from tobacco-free nicotine pouches compared to American moist snuff pouchesISRCTN13527565Swedish Match35
已完成
不适用
A study investigating the uptake to the blood circulation of nicotine from tobacco free nicotine pods compared to tobacco-based Swedish snus and American moist snuffTobacco useISRCTN77807609Swedish Match Europe Division36
进行中（未招募）
不适用
icotine plasma concentrations and subjective effects of a single dose of Nicachet 4 mg nicotine oromucosal powder in pouch compared with 4mg Nicorette chewing gum and 1mg Nicorette nasal spray. - Nicotine oromucosal powder in pouchSmoking cessationEUCTR2010-024445-78-SEMagle AB20